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Abstract
Venous Thromboembolism (VTE) is a disease responsible for more than 100,000 deaths
a year in the U.S [1]. Thru early detection, this mortality rate can be decreased as
the early administration of therapeutic heparin can prevent VTE from being fatal.
However, this can be challenging in a surgical ICU setting where symptoms can hard
to distinguish from common ICU patient symptoms [2]. In this work, we developed
a risk prediction model and a novel real time classification model to determine the
risk of VTE. The risk prediction model analyzes patient demographic and history
data to determine if they are at a high risk. Meanwhile, the real time classification
model analyzes high frequency physiological time series data to determine if a patient
is currently experiencing a VTE. The findings from this study and model will be
implemented as a screening tool to assist clinicians in determining which patients
require additional care.
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Venous Thromboembolism (VTE) is a common but preventable disease that encom-
passes two medical complications, Deep Vein Thrombosis (DVT) and Pulmonary
Embolism (PE). In a 2008 Report, the Surgeon General of the United States ap-
proximated that VTE accounts for more than 100,000 deaths per year in the US
[1]. Healthcare associated VTE risk is increased by surgery, trauma, or prolonged
bed-rest, thus putting most patients in a surgical ICU at increased risk for VTE [2].
Furthermore, out of all patients who have symptoms of VTE, only 25% of symptomatic
patients actually have a thrombus, thus making the disease hard to distinguish from
common symptoms patients experience in the ICU [2]. In hospitalized patients, most
VTE presents as a Deep Vein Thrombosis, or Pulmonary Embolism. Most of the
serious morbidities and mortality are related to PE, which can prevent blood flow to
the lungs. The most effective prophylaxis and treatment for VTE is to administer
heparin, however this intervention comes with a serious risk of bleeding complications
[3]. Additionally, approximately 5% to 10% of patients treated with heparin for
thrombosis develop thrombocytopenia, a morbid complication involving low platelet
count [4]. Therefore, there has been an emphasis placed on developing and using Risk
Assessment Models (RAMs) to ensure that VTE prophylaxis is appropriately provided
to hospitalized patients. Currently there is no standard risk assessment model for
VTE in a hospitalized [5] or ICU setting. For a majority of ICU patients, the standard
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therapy is a combination of pharmacologic and mechanical prophylaxis. In spite of
this, almost 10% of surgical ICU patients have a VTE incident [6]. In post-surgical
patients, risk assessment and bedside diagnosis is particularly problematic, as this
patient population has preexisting risk factors that include tissue injury, stasis and
many also have a cancer diagnosis, all of which are known to increase the probability
of a VTE. In addition the usefulness of D-dimer, a test measuring fibrin deposition
indicative of thrombus formation [7], in risk assessment algorithms is usually min-
imized by its elevation following surgery. Current machine learning methods are
specified for Risk Prediction rather than Real Time Analysis, and provide information
for specific scenarios, such as using Risk Assessment Models (RAMs) for VTE in
post-chemotherapy cancer patients [8] or predicting VTE complications following
Posterior Lumbar Spine Fusion surgery [9]. Outpatient clinical scoring systems such as
the Modified Wells’ Criteria have poor sensitivity in intensive care settings as several
of the risk factors that influence the probability of the disease are already present
in a majority of patients. Futhermore, machine learning approaches for VTE risk
stratification utilize components of the Wells’ score and thus face many of the same
difficulties in application to the ICU setting [10]. More complex risk assessment models
such as the Caprini model and Padua prediction score have improved performance
over these clinical scoring systems but still have significant room for improvement
in sensitivity, specificity, and patient outcomes [11–13]. The common factor of the
currently available models is their use of static data measurements to approximate
risk throughout the patients stay, and thus more effective in an out-patient medical
settings and do not apply well to critically ill patient populations, causing clinicians
to struggle to accurately detect VTE. Moreover, diagnosis of VTE is typically in the
late stages as the onset of the disease is often asymptomatic. The current diagnostic
approach is dependent on patient reported symptoms as well as physiologic parameters.
Therefore, developing a robust and comprehensive predictive analysis algorithm can
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inform doctors in advance whether or not patients are at an increased risk of developing
VTE, and start treatment early.
The development of VTE is a dynamic process and coagulability can change on a
daily basis. There are vast amounts of real-time data produced by patients in the ICU
that currently is unused in the assessment of risk for VTE. The inclusion of these time
varying parameters will improve the specificity of previous risk assessment models, and
will lead to the development of a real-time risk prediction system for VTE that takes
into account the daily fluctuations in the patient’s physiologic state. The objectives of
this study were to determine if the inclusion of an expanded feature set in non-biased
mathematical models could improve on the current performance of existing RAMs
when applied in ICU patients and if the addition of physiologic time series (PTS) data





The data used was collected between 2016 and 2017 using the Anesthesia Quality
Improvement data base of the Department of Anesthesiology and Critical Care
Medicine at Johns Hopkins School of Medicine. The data set was de-identified before
use and contains 10,180 unique patients’ data.
2.2 Preprocessing Data and Cohort Definitions
The categorization of VTE encompasses two clinical outcomes, PE and DVT. ICD 10
codes were used to identify positive VTE patients.
The codes, located in Table 2-1, were narrowed down to new, acute VTE, excluding
codes for chronic VTE, septic PEs, and codes relating to superficial veins. After
filtering by ICD 10 Codes, 265 VTE patients were identified with 135 DVT patients,
87 PE patients and 43 DVT + PE patients. Figure 2-1 depicts the filtration process.
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Table 2-1. ICD10 Codes
ICD10 Codes









Figure 2-1. Patient Cohort Selection for VTE Risk Prediction
The set of inclusion/exclusion criteria described in Figure 2-1 was used to generate
a population for the development of a preliminary risk assessment score. In order to
determine proper time windows for the time sensitive VTE classification model, a
more rigorous approach was needed. Patients were screened by their ICD-10 codes,
then further screened by the presence of an imaging scan and therapeutic heparin
administration. Through this filtration process, depicted in Figure 2-2, 51 VTE
patients were identified within in the original population, with 26 new DVT, 18 new
5
PE, and 7 new DVT+PE patients.
Figure 2-2. Patient Cohort Filtration for Real-Time VTE Classification
For the Risk Prediction Model, the following nine data categories were extracted:
age, sex, weight, height, ASA Physical Status, smoking history, race, type of surgery,
and the patient’s comorbidities at the time of their admission to the hospital. These
nine data categories corresponded to 96 features for modeling since patients could
have multiple features in some of the categories. For example, comorbidities were
administratively assigned to patients using the set of 30 Elixahuser comorbidity
measures [14]. The Real-Time VTE Classification included an additional six statistical
elements derived from physiologic time-series data. These data elements were: Arterial
Mean Blood Pressure, Arterial Systolic Blood Pressure, Arterial Diastolic Blood
Pressure, Oxygen Saturation, Heart Rate and Respiratory Rate, which were extracted
using the R-package tsfeatures [15].
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2.3 VTE Risk Prediction Model
The first goal was to develop a generalized risk assessment model to estimate the prob-
ability of a post-surgical ICU patient developing a VTE during their hospitalization.
Selection of data inputs for this model was based on the Caprini and Wells models,
which incorporate data elements such as Age, Sex, BMI, and ASA Physical Status
[10–13]. In addition the model also incorporated additional data elements such as the
type of surgery, length of surgery and associated comorbidities.
The patient level data was distributed across multiple sources (DxPx.txt, Elixahuser-
CobMorb.txt, Height.txt), which were consolidated into a single R data-table. Patients
were then either identified or labelled as having a VTE (positive) or not having a VTE
(negative). Positive patients were further classified as having either a DVT or PE.
Patients were identified as having a VTE by using the corresponding ICD10 codes.
Because of the differences in patho-physiology and outcomes, two separate risk models
were constructed, one for PE and one for DVT.
The data was heavily imbalanced with 265 positive VTE patients and 9370 negative
patients. Therefore, the models had a strong potential to over-fit the data. In order
to prevent this, various sampling methods were implemented in order to balance the
dataset. Methods included were: up sampling, down sampling, Synthetic Minority
Oversampling Technique (SMOTe), Random Oversampling Examples (ROSE) and a
custom ensemble classifier that combined the previous four methods.
Up sampling is the method of randomly duplicating observations in the minority
class to achieve an evenly balanced data set. Down sampling is the method of randomly
selecting a subset of observations in the majority class to reach an evenly balanced
data set. SMOTe uses machine learning techniques to create artificial data points
in the data set. SMOTe accomplishes this by implementing a K-Nearest Neighbor
(KNN) algorithm to map all the observations into sets of clusters, and then develops
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artificial data points using inference of an observation and its closest nearest neighbors.
ROSE similarly develops artificial data points, however instead of a machine learning
approach, ROSE uses underlying statistical information to develop data points. ROSE
accomplishes this by creating a probability distribution of observations from both
classes, and then extracting samples from the distribution to develop artificial data.
Finally, a combination of Up, Down, SMOTe, and ROSE sampling methods, called
the Ensemble Sampling Method, was tested.
Four different classifiers were tested to determine the best VTE Risk Prediction
Model: Random Forest (RF), Generalized Linear Models (GLM), Support Vector
Machines (SVM), and Gradient Boosting Machines (GBM). GLM is the standard
approach that was implemented first. Random Forest and GBM were then implemented
after researching their effectiveness in predicting clinical infections in other clinical
papers [16, 17]. However, it became apparent after a couple of tests that a linear
classifier such as GLM performed better than the RF and GBM, more linear classifiers
were explored and the SVM linear classifier was implemented in the training process.
The data was finally split into 75/25 testing and training subsets.
In order to benchmark the classifiers, four statistical properties of the classifiers were
compared to determine the model classifier: Sensitivity, Specificity, AUC and Balanced
Accuracy. Sensitivity, or True Positive Rate, is the proportion of correctly identified
positive VTE patients to the actual number of positive VTE patients. Specificity, or
True Negative Rate, is the proportion of correctly identified negative VTE patients to
the actual number of negative VTE patients. AUC, or Area Underneath the ROC
Curve, measures the ability of the classifier to distinguish between a positive VTE
instance and a negative VTE instance, the higher the number the better the classifier
is able to distinguish between the two instances. Balanced Accuracy is the number
of correctly classified instances of VTE to the observed instances of VTE, calculated
as the average of the Sensitivity and Specificity. Balanced accuracy differs from
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normal accuracy as it removes any bias caused by an imbalanced class. Full statistical
information including Positive Predictive Value (PPV), Negative Predictive Value and
Mcnemar’s Test P-Value are located in the Appendix I.
2.4 Real Time VTE Classification Model
The second goal was to develop a Real-Time VTE Classification Model to determine
whether or not the patient is experiencing a VTE at the time of the assessment. This
was accomplished by analyzing high-frequency physiological time-series data captured
via instruments directly attached to the patient. This allowed the model to provide
updated prediction of a patients VTE status throughout their ICU stay.
Current VTE diagnostic measures do not establish a precise disease onset time, as
diagnosis is performed re-actively based on signs and symptoms rather than proactively.
Standard diagnostic measures include a Computed Tomography (CT) with Intravenous
(IV) contrast, an ultrasound duplex scan, or an echocardiography. The time stamps
of these studies can provide an indication of disease onset time.
However scans can be ordered for multiple reasons, especially in surgical-ICUs,
where clinicians routinely scan patients. The outcome or cause of the study is
infrequently documented in clinical notes. Therefore, in order to infer that the study
was for VTE, the study is typically succeeded by the administration of IV heparin or
low molecular weight heparin. Thus for the purpose of the this study, it was assumed
that the order of therapeutic heparin within 24 hours of a diagnostic study time stamp
was representative of VTE treatment.
Applying this methodology, 51 VTE positive patients were identified with appropri-
ate corresponding time stamps. Time stamps can be used to determine VTE positive
windows, periods of times when the patients is experiencing the signs and symptoms
of VTE, which are used as classification labels for model development. Data was
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recorded on a minute to minute basis, as such time stamps are accurate to the nearest
minute. Because of the low number of total observations for this section, both the PE
and DVT cohorts were merged.
Some assumptions had to be made in order to determine proper VTE positive
windows. Based on the knowledge of clinical workflows, a positive VTE window for
a DVT patient is 24 hours before and after diagnosis time, but the positive VTE
window for a PE patient is 6 hours before and after diagnosis time. This is because
PE is a more life threatening condition, and as such the response to an order for the
exam and the initiation of therapy after a diagnostic exam are typically much faster.
The six physiological markers in the PTS data set are Arterial Blood Pressure
Systolic, Arterial Blood Pressure Diastolic, Arterial Blood Pressure Mean, Respiratory
Rate, Heart Rate, and Oxygen Saturation Level (SPO2). In order to consolidate the
time series data set, the R tsfeatures package was used [15]. This package extracted
16 time series statistical features physiological per marker resulting in a total of 96
features.
Subsequently, a classification model was developed that would determines if a
patient is experiencing a VTE based previously correlated observations. Classifiers
such as Random Forest, K-Nearest Neighbors (KNN), and Naive Bayes (NB), were
finally selected based on previous literature in addition to its training performance.
Random Forest has shown promise in analyzing time series information for detecting
Alzheimer’s disease [18], while K-NN has been effectively implemented in analyzing
ECG data to determine abnormal brain activity [19]. Naive Bayes was selected not
only for its promise in analyzing clinical time series data [20], but also its effectiveness
in predicting heart disease [21]. Similar to the VTE Risk Prediction Model, classifiers




In order to determine the best VTE Risk Prediction Model, four different classifiers
were tested, Random Forest, Support Vector Machines, Generalized Linear Models,
and Gradient Boosting Machines. Subsequently, to determine the best Real Time VTE
Classification Model, three different classifiers were tested, Naive Bayes, K-Nearest
Neighbors and Random Forest.
3.1 VTE Risk Prediction
The VTE Risk Prediction Model was split into two sub-models: DVT Risk Prediction
Model and PE Risk Prediction Model.
3.1.1 DVT Risk Prediction Model
3.1.1.1 Training
Table 3-1 shows the number of positive DVT patients and negative DVT patients for
the each of the different sampling methods.
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Table 3-1. DVT Sampling Statistics
DVT Sampling Statistics
Sampling Technique Positive Negative
No Sampling 134 7093
Up Sampling 7093 7093




The results for No sampling, Up sampling, and Down sampling are previously
defined. The SMOTe and ensemble techniques led to a decrease in the total num-
ber of observations, while the ROSE technique yielded the same number of overall
observations.
Table 3-2 and Figure 3-1 details the statistics and ROC curve of the best performing
sampling method for each classifier, respectively. Training statistics and ROC curve
were calculated for the in sample population. The GBM ensemble classifier was the
best training model. More detailed statistics and ROC Curves for all classifiers are
listed in Appendix I and Appendix II.




Sensitivity Specificity AUC Balanced
Accuracy
GLM Up 0.708 0.560 0.715 0.634
SVM Up 0.734 0.783 0.831 0.756
GBM Ensemble 0.844 0.980 0.965 0.912
RF Up 0.823 0.908 0.951 0.866
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Figure 3-1. Best Performing DVT Training Classifiers
3.1.1.2 Testing
The model was tested on a previous withheld out of sample subset population, which
had 44 positive and 2364 negative DVT patients. Table 3-3 and Figure 3-2 details
the statistics and ROC curve for the best performing sampling method for each
classifier. The SVM classifier with ensemble sampling was the best testing classifier.
Test statistics and ROC curves for each tested classifier are available in Appendix I
and Appendix II.




Sensitivity Specificity AUC Balanced
Accuracy
GLM ROSE 0.522 0.767 0.7074 0.645
SVM Ensemble 0.590 0.725 0.6721 0.659
GBM Down 0.590 0.622 0.6743 0.606
RF Down 0.431 0.811 0.698 0.621
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Figure 3-2. Best Performing DVT Testing Classifiers
3.1.1.3 Feature Importance
Table 3-4 indicates the top three ranked features for each DVT classifier. Feature
Importance was calculated through the use of the R varimp function in the caret
package. Overall, weight loss was a vital factor in predicting DVT prior to admissions,
with three of the four classifiers ranking it as the most important feature. Full feature
importance information is located in Appendix II.
Table 3-4. DVT Risk Prediction: Feature Importance
DVT Feature Importance Ranking
Feature
Rank
GLM SVM GBM RF
1 Oncology Weight Loss Weight Loss Weight Loss
2 PE History ASA Physical
Status
Surgery Length Surgery Length
3 Ophthalmology Surgery Length Oculoplastics PE history
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3.1.2 PE Risk Prediction Model
3.1.2.1 Training
Table 3-5 is a table of the number of PE and Non-PE patients for each of the different
sampling methods.
Table 3-5. PE Sampling Stats
PE Sampling Ratios
Sampling Technique Positive Negative
No Sampling 98 7129
Up Sampling 7129 7129




The results for No sampling, Up sampling, and Down sampling are previously
defined. The SMOTe and ensemble techniques led to a decrease in the total num-
ber of observations, while the ROSE technique yielded the same number of overall
observations.
Table 3-6 and Figure 3-3 display the statistics and ROC curve for the best
performing sampling method for each classifier, respectively. Training statistics
and ROC curves were calculated using the in sample population. The GBM SMOTe
and RF ROSE classifiers both were the best performing classifiers for this section.
Further statistical information and ROC curves,for all classifiers are located in the
Appendix I and Appendix II.
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Sensitivity Specificity AUC Balanced
Accuracy
GLM Up 0.480 0.821 0.736 0.650
SVM Up 0.840 0.753 0.844 0.797
GBM Smote 1.000 1.000 1.000 1.000
RF Rose 1.000 1.000 1.000 1.000
Figure 3-3. Best Performing PE Training ROC Curve Classifiers
3.1.2.2 Testing
The classifiers were tested on the withheld out of sample population of 32 positive
and 2376 negative PE patients. Table 3-7 and Figure 3-4 shows the statistics and
ROC curve for the best performing sampling methods per classifier. Overall the
best performing classifier was the GBM classifier with down sampling. Statistics and
ROC curves for all classifiers and sampling methods can be found in Appendix I and
Appendix II.
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Sensitivity Specificity AUC Balanced
Accuracy
GLM Ensemble 0.625 0.627 0.652 0.626
SVM Ensemble 0.562 0.683 0.682 0.623
GBM Down 0.687 0.558 0.658 0.623
RF Down 0.343 0.800 0.680 0.572
Figure 3-4. Best Performing PE Testing ROC Curve Classifiers
3.1.2.3 Feature Importance
Table 3-8 are the top three ranked features for each PE classifier. Feature importance
was calculated through the varImp function in the R caret package. Overall, surgery
length played a vital role in predicting VTE, being top feature in two different classifiers.
Full feature importance information is available in the Appendix II.
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Table 3-8. PE Risk Prediction: Feature Importance
PE Feature Importance Ranking
Feature
Rank
GLM SVM GBM RF
1 PE History White Caucasian Surgery Length Surgery Length
2 Orthopedics Weight Never Smoker Peripheral vascu-
lar disease






3.2 Real-time VTE Classification Model
3.2.1 VTE
3.2.1.1 Training
Table 3-9 and Figure 3-5 detail the training performance and ROC curves of the three
classifiers trained for Real Time VTE Classification Model. Training performance and
ROC curves are calculated on the in sample population. The best performing training
classifier was the Random Forest classifier.
Table 3-9. VTE Real Time Training Results
VTE Real Time Training Results
Classifier Sensitivity Specificity AUC Balanced
Accuracy
K-NN 0.933 0.705 0.858 0.820
Naive Bayes 0.571 0.892 0.903 0.732
Random Forest 0.771 0.982 0.985 0.876
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Figure 3-5. Real Time VTE Training ROC Curves
3.2.1.2 Testing
Classifiers were tested on a previously withheld out of sample population. Table 3-10
and Figure 3-6 details the testing performance and ROC curves of the three classifiers
tested for Real Time VTE Classification Model. The best performing classifier in the
testing phase was the Naive Bayes classifier.
Table 3-10. VTE Real Time Testing Results
VTE Real Time Testing Results
Classifier Sensitivity Specificity AUC Balanced
Accuracy
K-NN 1.000 0.500 0.749 0.750
Naive Bayes 1.000 0.900 0.947 0.950
Random Forest 0.667 0.900 0.913 0.783
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Figure 3-6. Real Time VTE Testing ROC Curves
3.2.1.3 Feature Importance
Table 3-11 detail top three ranked features per classifier Feature importance was
calculated using the varImp function found in the R caret package. Overall, the
most important physiological time series variable was Respiratory Rate, with all three
models ranking it as the top feature. More detailed feature importance information
can be found in Appendix II
Table 3-11. VTE Real Time Classification: Feature Importance































The importance of preventing and diagnosing VTE has been highlighted by numerous
public health agencies including the Surgeon General of the United States [1], the
National Institutes of Health, and the National Clinical Guideline Center (UK) [22].
VTE is both many times more prevalent and morbid in the critically ill than in
hospitalized patients or the general public [23–26]. In addition, it is well recognized
that the incidence of VTE is increased by surgery. In spite of this need, there are no
highly specific and sensitive tools for assessing which patients are at risk for developing
a VTE while in recovery in the surgical ICU. Thus, it was postulated that training a
machine algorithm with a very wide set of critical care patients data could improve
on current VTE risk models.
To accomplish this, two separate VTE models were constructed, a VTE Risk
Prediction Model and a Real Time VTE Classification Model. The VTE Risk Pre-
diction Model was further segmented into a DVT Risk Prediction Model and a PE
Risk Prediction Model. For the DVT Risk Prediction Model training phase, the best
performing classifier was the GBM with Ensemble sampling boasting the following
metics: sensitivity of 0.844, specificity of 0.980, AUC of 0.965 and balanced accuracy of
0.912. However in the testing phase the best performing classifier was GBM with down
sampling boasting following metrics: sensitivity of 0.590, specificity of 0.725, AUC of
0.6721 and balanced accuracy of 0.659. A possibility as to why there is a discrepancy
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between testing and training is due to artificial data observations introduced in various
sampling methods, which are easier to classify then actual observations. Furthermore,
models perform better on training datasets than testing datasets because models built
on training datasets and are much better optimized for it. Meanwhile, in the PE Risk
Prediction Mode training phase, the best performing was the both the GBM classifier
with SMOTe sampling and RF classifier with ROSE sampling, boasting the following
metrics: sensitivity of 1.000, specificity of 1.000, AUC of 1.000 and balanced accuracy
1.000. One possibility as to why these two classifiers had perfect accuracy is because
of the sampling methods. Both SMOTe and ROSE implement artificial observations
derived from machine learning models or probability distributions rather than true
observations, and thus making it easier for the classifier to correlate. However, per-
formance analyzing artificial observations is not direct correlation to analysis of true
observations, which were used for the testing phase of the model. In the testing phase,
the best performing classifier was the GBM classifier with down sampling, boasting
the following metrics: sensitivity of 0.687, specificity of 0.558, AUC of 0.658, balanced
accuracy of 0.623. In comparison, current VTE RAMs analyze thrombosis markers to
discriminate between VTE and non-VTE in a critically ill patients boast the following
metrics: sensitivity of 0.660, specificity of 0.606, and an AUC of 0.696 [13].
Furthermore, the Real Time VTE Classification Model, which analyzes high-
frequency physiological time series data, was significantly better in detecting if a
patient was experiencing a VTE than current Risk Assessment Models, including those
that were tested in this study. This is the first time that disease onset and physiological
time series data has been incorporated into a VTE analysis and potentially allows the
model to be used as a diagnostic screening tool rather than as simple risk analysis
tool. In the testing phase, the strongest classifier was the K-NN, with a sensitivity
of 0.933, a specificity of 0.705, an AUC of 0.858 and a balanced accuracy of 0.820.
Meanwhile, the Naive Bayes was the best tested classifier, boasting a sensitivity
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of 1.000, sensitivity of 0.900, AUC of 0.947 and a balanced accuracy of 0.950. In
conclusion, the results presented were promising as it indicated that the inclusion
of real time physiological time series will significantly improve the performance over
current VTE risk assessment models.
For this novel approach, we applied assumptions about clinical workflow to our
interpretation of the physiological time series data. This allowed us to assign a
window of time in which the diagnosis of VTE was likely to have been made in our
retrospective PTS data. The selection of data elements was informed by existing
models and expanded to include elements that were collected in the medical record.
The models did not assign any predetermined weight to input features. The routine
use of ultrasound for VTE screening or diagnosis in critically ill patients is not
recommended because it is believed that it will result in complications from treatment
of VTE [27]. As a result, many risk assessment models (RAMs) have been created
with the goal of using patient risk stratification to guide appropriate pharmacologic
VTE prophylaxis or diagnostic screening. The value of these RAMs in general and in
specific patient populations remains at issue. For example, Greene et al compared the
discrimination and calibration of 4 widely used VTE RAMs applied retrospectively to
general medical patients and found that discrimination was poor for all models and
concluded that the existing RAMs, “. . . are suboptimal and are deserving of further
enquiry”, especially in critical illness and surgery because these conditions increase the
risk of developing VTE [12, 28]. Furthermore, while pharmacologic DVT prophylaxis
does not appear to increase the risk of significant postoperative bleeding this risk
continues to impact prophylaxis [29–32].
This new model incorporated features that are clinically associated with the
increased risk of VTE and are included in existing RAMs. Among the many VTE
RAMs, the Caprini score has been the best validated and examined in post-surgical
patients [11, 33–35].The Caprini model applied consensus guidelines about VTE risk
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to create a scoring system in which clinical and patient-related factors are weighted
[36]. However, the inclusion of the Elixhauser comorbidity features in our model allows
a broader and less biased description of a patient’s clinical state [14]. In addition, the
complexity and lack of specificity of Caprini and other scoring systems have limited
their utility in post-operative surgical populations. This complexity may explain
why physician calculations of the Caprini scores of surgical patients were found to be
inaccurate when compared to a validated computer calculation [37]. Importantly, one
study of the Caprini score in surgical ICU patients found that the VTE rates were
higher in surgical ICU patients for the same scores and suggested that this is probably
due to the presence of risk factors that are not accounted for in the scoring system [38].
The combination of universally available patient data and the automation of processing
this data may add to the clinical utility of the RAMs described in this work. This new
models also have the advantage of ordering the importance of features contributing to
VTE in post-surgical critical care patients. This method, known as feature importance,
ranks features based on the calculated weights of features determined at training. This
gives insight on the decision-making process our model uses when determining if a
patient is at risk for VTE, and allows us to compare our model with previous work.
For example, Obi and colleagues performed a validation of the Caprini VTE RAM in
Critically Ill Surgical Patients and determined that factors such as age, weight, BMI,
presence of tumor, major surgery (> 45 mins), history of DVT or PE and for female
specifically, the use of oral contraceptives or pregnancy are important. Furthermore, a
paper published by Wells detailing the risks associated with pulmonary embolisms
found that patients with cancer, previous DVT or PE, or those who are immobilized
due to surgery have increased risk of developing a PE. Subsequently,this aligned with
our non-priori weighted model, which highly ranked weight, PE history and surgery
length. However, it should be noted that these features list comparisons are not one
to one due to differentiating criteria. Other models, such as Wells and Caprini, have
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looked at previous surgery as a feature, whereas all of our subjects have had surgery.
As such, many of the previous models may not be compatible with our research data.
This speaks to the novelty of our model, as it attempts the more challenging endeavor
of classifying patients in a highly prevalent VTE environment, that are already at a
higher risk of developing VTE. As such our data-set was a collaboration of features
partly from previous models, collected patient commodities and selected data related
specific for surgeries.
There is variation in the ranked feature importance within the DVT and PE models,
despite classifying on the same dataset. This is part in due because each classier has
different methods to determine feature importance, which is calculated as a correlation
between dependent and independent variables. For example, linear models such as
GLM used the t-statistic test, T-Test, to determine feature ranking, however in contrast
Random Forest model, determines feature importance by determining the maximum
decrease in classification accuracy when the feature is excluded. More importantly,
these models are fundamentally different implementing different methodology and
algorithms to classify patients. This difference in approach lead to variances in the
feature weight ranking among classifiers. Having models with different ranked features
can provide insight into correlations between features and VTE probability that were
previously unknown.
In order to improve the use of RAMs, new models have been developed to simplify
data elements and condition labeling. For example, Mlaver and colleagues performed a
multivariate regression of NSQIP data to create a 5 component RAM for preoperative
risk assessment of surgical patients. The simple COBRA model created by these
authors was highly sensitive but had low specificity for peri-operative VTE risk [39]. In
our RAMs for DVT and PE we have generally increased the number of data categories
and accordingly the number of potential data elements. However, these elements are
required components of patient records (clinical and administrative). Thus, the RAMs
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presented in this work do not require the bedside clinician to interpret the patient’s
condition as part of the RAM. In addition, like other statistical scoring systems, our
model is not dependent on a priori factor weights but rather uses the existing data set
to develop a non-biased model.
Existing RAMs also suffer from a comparative lack of specificity, especially when
applied to surgical or critically ill patients. Fu and colleagues highlighted this issue in
a retrospective study of 151 patients in which they found that 88% of patients who
did not have VTE had a Caprini score that placed them in the high or highest risk
categories which amounted to a test specificity of 17% [13]. Similarly, Xu et al found
that in post-cancer surgery ICU patients only approximately 3% had “symptomatic”
VTE but 99.5% had the highest risk Caprini score [40]. Several groups have attempted
to improve the specificity of RAMS by incorporating thrombosis bio-marker data in
their RAM models. Fu et al suggested that the risk assessment correlates closely to
serum levels of thrombosis markers especially thrombomodulin and that these can
improve test specificity [13]. Similarly, Wang et al found that increased D-Dimer
levels on post-operative day 5 in patients who underwent thoracic tumor surgery were
independently correlated with DVT [41].
While DVT and PE are collectively included in the diagnosis of VTE and are
intimately related they are not identical conditions. For this reason we disassociated
these two diagnoses for the purposes of creating novel RAMs. This disassociation has
both practical and clinical advantages. First, our algorithms can theoretically achieve
higher specificity by considering DVT and PE independently since the conditions that
lead to each outcome are likely to be different. Second, since PE is less prevalent than
DVT the class imbalance inherent in model creation can be better recognized and
mitigated. Finally, since RAMs for VTE are used to principally to guide prophylactic
therapy, understanding the risk of suffering a PE rather than a DVT may impact
decisions about chemo prophylaxis.
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In the second phase of this work, patients were classified as as being in the VTE
time window through analysis of physiological time series data (PTS). Eventually
such a model could be applied to perform real time risk scores by analyzing the PTS
data. While, previous scoring systems have used the concept that VTE disease does
perturb cardiopulmonary status, the inclusion of PTS data in our model is a significant
departure from previous VTE risk and likelihood scoring systems [42–44]. Here, we
hypothesized that evidence of VTE is embedded within the PTS signals and that
these may be discovered using advanced statistical techniques. We chose to use the
twenty-four and six hour time windows around the clinical diagnosis of a DVT or
PE, respectively, based on our perceptions of clinical workflows and the time to reach
therapeutic goals with anticoagulants. Using this data we were able to create a Naïve
Bayes machine learning model for VTE that has a very high accuracy and AUC for
the ROC.
Clinical risk assessment for VTE using Artificial Intelligence in the form of neural
networks has recently shown promise. For example, the Oxford Neural Network (ONN)
is a DVT risk assessment model built on an artificial neural network using data of
patients referred for DVT evaluation to an outpatient thrombosis clinic [10], The input
layer of the ONN includes the data elements for Wells’ criteria and the patients’ age
and gender. The ONN retains very high sensitivity and importantly may also improve
specificity since it excluded 37.5% of patients who would have undergone unnecessary
ultrasound exam [10].
An Artificial Neural Network (ANN) for VTE in hospitalized patients was created
by Qatawneh et al who applied 35 elements from the Caprini score to an ANN that
was trained using the records of only 150 hospitalized patients [45].Each input neuron
was encoded with a perceived weight before analysis to produce an overall agreement
with manual Caprini risk scoring of 81% [45]. Similarly, Martins and colleagues used
data from 261 in-patients who had previously suffered VTE and combined Principle
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Component Analysis with ANN to create models for to evaluate the risk of recurrence
that had an accuracy of 92.8% or greater [46].
There are several limitations to our work and some of them are related to the use of
retrospective data for the diagnosis of VTE. The diagnoses of VTE in the RAMs that
we created using static data are completely dependent on the use of ICD 10 codes. In
a previous study using ICD 10 codes as a marker of postoperative VTE their positive
predictive value (PPV) was only between 44 – 48% [47]. This low PPV based on ICD
codes could explain the lower than expected VTE rate of 2.8% in our patient cohort.
Our model for PTS data used the combination of an ICD code for VTE in combination
with a diagnostic study and the initiation of anticoagulant therapy. The coupling
of ICD codes with diagnostic studies has been previously demonstrated to be both
sensitive and specific [48]. In our data s we can’t know the number of undetected or
unaccounted VTE events. Undetected VTEs occur when a patient with an occult VTE
does not undergo a diagnostic study while unaccounted VTEs can occur because of
administrative coding deficiencies. In addition, by adding the requirement in the PTS
data model that a patient initiate anticoagulant therapy we exclude the possibility
that a patient has a VTE but that anticoagulation is contraindicated. The study is
also limited by the relatively low number of VTE events which resulted in the class
imbalance that we treated with sampling methods. Such treatments can result in over
fitting of data in machine learning models. Finally, this study was conducted at a
single, academic, tertiary hospital. Approaches to VTE prophylaxis and diagnosis
are likely to vary significantly between healthcare institutions and future study will





The proposed model helps to address a serious issue critical care patients and doctors
face, as Venous Thromboembolism is serious disease with life threatening consequences.
The proposed system provides an additional layer of screening in order to assist
clinicians in determining if the patient is at risk of developing a VTE. Currently,
there is no standard for VTE risk assessment for critical care patients, and patients
are screened for various reasons under various different circumstances. The lack of
standard risk assessment procedure can lead to missed disease diagnosis which can be
deadly for the patient. The proposed system is a two part model; the first part VTE
Risk Prediction Model, a model predict the risk of a patient developing a VTE prior
to entrance to the ICU and a; Real Time VTE Classification: a model that provides
real time updates to the risk by analyzing high frequency physiological time series
data. This cohesive system will help to provide a basis for clinicians to use when they
are faced with the critical decision of determining if a patient is experienci ng a VTE.
Furthermore, this system will monitor the patients VTE status even when support
staff such as clinicians and nurses are not actively monitoring the patient. Overall, the
results of this study were promising and showed that the analysis of the high-frequency
real time physiological data significantly improves the models performance compared
to existing RAMs and can be used as a diagnostic screening tool.
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Appendix I
Tables and Confusion Matricies
A. VTE Risk Prediction
A..1 DVT Models
A..1.1 GLM














Pos Pred Value NaN


















Pos Pred Value 0.039
Neg Pred Value 0.980
Mcnemar’s
Test P-value <2e-16














Pos Pred Value 0.036


















Pos Pred Value 0.040
Neg Pred Value 0.989
Mcnemar’s
Test P-value <2e-16
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A..1.2 SVM Linaer Models














Pos Pred Value NaN
Neg Pred Value 0.982
Mcnemar’s
Test P-value 9.022e-11
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Pos Pred Value 0.031
Neg Pred Value 0.989
Mcnemar’s
Test P-value <2e-16
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Pos Pred Value 0.044
Neg Pred Value 0.958
Mcnemar’s
Test P-value <2e-16
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Pos Pred Value NaN
Neg Pred Value 0.982
Mcnemar’s
Test P-value 9.022e-11
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Pos Pred Value 0.018
Neg Pred Value 0.987
Mcnemar’s
Test P-value <2e-16
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Pos Pred Value 0.048
Neg Pred Value 0.986
Mcnemar’s
Test P-value <2e-16
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A..1.4 Random Forest Models














Pos Pred Value NaN
Neg Pred Value 0.982
Mcnemar’s
Test P-value 9.022e-11
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Pos Pred Value 0.041
Neg Pred Value 0.987
Mcnemar’s
Test P-value <2e-16
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Pos Pred Value 0.077
Neg Pred Value 0.982
Mcnemar’s
Test P-value <2e-16
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Pos Pred Value 0.NaN
Neg Pred Value 0.988
Mcnemar’s
Test P-value 4.251e-8
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Pos Pred Value 0.021
Neg Pred Value 0.991
Mcnemar’s
Test P-value <2e-16
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Pos Pred Value 0.024
Neg Pred Value 0.988
Mcnemar’s
Test P-value <2e-16
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Pos Pred Value NaN
Neg Pred Value 0.986
Mcnemar’s
Test P-value 4.251e-8
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Pos Pred Value 0.021
Neg Pred Value 0.990
Mcnemar’s
Test P-value <2e-16
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Pos Pred Value 0.022
Neg Pred Value 0.988
Mcnemar’s
Test P-value <2e-16
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Pos Pred Value NaN
Neg Pred Value 0.987
Mcnemar’s
Test P-value 4.251e-18
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Pos Pred Value 0.020
Neg Pred Value 0.992
Mcnemar’s
Test P-value <2e-16
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Pos Pred Value 0.038
Neg Pred Value 0.988
Mcnemar’s
Test P-value <2e-16
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A..2.4 Random Forest Models














Pos Pred Value NaN
Neg Pred Value 0.986
Mcnemar’s
Test P-value 4.25e-08
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Pos Pred Value 0.022
Neg Pred Value 0.989
Mcnemar’s
Test P-value <2e-16
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Test P-value <2e-16
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A. Venous Thromboembolism Risk Prediction
A..1 Deep Venous Thrombosis
A..1.1 Training
Figure II-1. GLM Training DVT ROC Curve
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Figure II-2. SVM Training DVT ROC Curve
Figure II-3. GBM Training DVT ROC Curve
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Figure II-4. RF Training DVT ROC Curve
A..1.2 Testing
Figure II-5. GLM Testing DVT ROC Curve
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Figure II-6. SVM Testing DVT ROC Curve
Figure II-7. GBM Testing DVT ROC Curve
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Figure II-8. RF Testing DVT ROC Curve
A..1.3 Feature Importance
Figure II-9. GLM DVT Risk Prediction Feature Importance
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Figure II-10. SVM DVT Risk Prediction Feature Importance
Figure II-11. GBM DVT Risk Prediction Feature Importance
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Figure II-12. RF DVT Risk Prediction Feature Importance
A..2 Pulmonary Embolisms
A..2.1 Training ROC Curves
Figure II-13. GLM Training PE ROC Curve
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Figure II-14. SVM Training PE ROC Curve
Figure II-15. GBM Training PE ROC Curve
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Figure II-16. RF Training PE ROC Curve
A..2.2 Testing ROC Curves
Figure II-17. GLM Testing PE ROC Curve
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Figure II-18. SVM Testing PE ROC Curve
Figure II-19. GBM Testing PE ROC Curve
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Figure II-20. RF Testing PE ROC Curve
A..2.3 Feature Importance
Figure II-21. GLM PE Risk Prediction Feature Importance
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Figure II-22. SVM PE Risk Prediction Feature Importance
Figure II-23. GBM PE Risk Prediction Feature Importance
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Figure II-24. RF PE Risk Prediction Feature Importance
B. Real Time VTE Risk Classification
B..1 VTE
B..1.1 ROC Curves
Figure II-25. Real Time VTE Training ROC Curves
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Figure II-26. Real Time VTE Testing ROC Curves
B..1.2 Feature Importance
Figure II-27. RF VTE Real Time VTE Risk Classification Feature Importance
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Figure II-28. NB VTE Real Time VTE Risk Classification Feature Importance
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unknown challenges. 
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AUGUST 2014 – DECEMBER 2018 
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AUGUST 2010 – MAY 2014 
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Research Intern | Johns Hopkins University  
SEPTEMBER 2019 – CURRENT |DR. ADAM SAPIRSTEIN 
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machine learning algorithms that analyzes high-frequency physiological time series data to 
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order to sense what the catheter tip is in contact with. By labeling and analyzing key frequency 
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Developed a software program in Java that runs as a plug-in under ImageJ (a Medical Image 
Analysis program from National Institutes of Health) to process MRI datasets to create maps of 
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• TensorFlow, Python 
• R and Shiny (for Web Interface) 
• MATLAB 
 
General Purpose Programming Languages 
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Engineering Application Software  
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• 3DS Max 
 
 SOCIAL SKILLS 
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MAY 2017 – MAY 2018 | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY 
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Volunteer | Tamil Entrepreneurs Forum (TEFCON) Conference 
SUMMER 2016 | TRENTON, NJ   
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Biographical sketch
As a Biomedical Engineering Student with a focus area in Data Science, I have the
experience and knowledge to carry the necessary tasks and requirements for the
proposed research project. Throughout my graduate studies, I have worked on various
Machine Learning and AI projects focused on improving healthcare needs of patients
as well making it easier for physicians to properly diagnose and treat patients. In these
projects I develop classification models to be used by clinicians in order to provide
clinicians additional information, such as the probability of a patient developing a
fatal disease during their admission in the hospital. Other projects include analyzing
radio signals from catheters to determine type of contact tissue as well as using image
classification models to classify Reagent T-cell images. My experience with machine
learning gives me the ability to address complex challenges. Artificial Intelligence is a
rapidly growing field and has shown to be vital in the health care setting to address the
needs healthcare workers face on the front line. As such, my expertise with Machine
Learning and Artificial Intelligence makes me a prime candidate in order to tackle the
problems and challenges in the following project.
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